Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Opus Genetics (IRD) Enterprise Value (2019 - 2026)

Opus Genetics has reported Enterprise Value over the past 13 years, most recently at -$60.0 million for Q1 2026.

  • Quarterly Enterprise Value fell 43.44% to -$60.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$60.0 million through Mar 2026, down 43.44% year-over-year, with the annual reading at -$45.1 million for FY2025, 48.7% down from the prior year.
  • Enterprise Value was -$60.0 million for Q1 2026 at Opus Genetics, down from -$45.1 million in the prior quarter.
  • Over five years, Enterprise Value peaked at -$14.0 million in Q3 2022 and troughed at -$60.0 million in Q1 2026.
  • The 5-year median for Enterprise Value is -$40.0 million (2023), against an average of -$37.1 million.
  • Year-over-year, Enterprise Value tumbled 203.89% in 2023 and then surged 39.97% in 2024.
  • A 5-year view of Enterprise Value shows it stood at -$42.7 million in 2022, then dropped by 18.35% to -$50.5 million in 2023, then surged by 39.97% to -$30.3 million in 2024, then crashed by 48.7% to -$45.1 million in 2025, then crashed by 32.97% to -$60.0 million in 2026.
  • Per Business Quant, the three most recent readings for IRD's Enterprise Value are -$60.0 million (Q1 2026), -$45.1 million (Q4 2025), and -$30.8 million (Q3 2025).